Atossa Therapeutics logo
Atossa Therapeutics
ATOS | NASDAQ
Chart Builder DCF Calculator
$1.93
-$0.03 (-1.53%)
At close: Nov 16, 2026, 4:00 PM ET
$1.96
+$0.03 (+1.55%)
After-hours: Nov 16, 2026, 5:35 PM ET

Atossa Therapeutics Company Profile

Company profile explained

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Key Executives

Name Position
Steven C. Quay FCAP Chairman, Chief Executive Officer & President
Mark Daniel Chief Financial Officer
Delly Behen Senior Vice President of Business Operations
Janet Rose Rea MSPH Senior Vice President of Research & Development
Richard Graydon Interim Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 09, 2026 8-K Current Report
Sep 29, 2026 8-K Current Report
Sep 18, 2026 8-K Current Report
Aug 07, 2026 8-K Current Report
Aug 07, 2026 10-Q Quarterly Report
Jun 12, 2026 424B5 Filing
Jun 11, 2026 8-K Current Report
May 14, 2026 4 Filing
May 14, 2026 4 Filing
May 14, 2026 4 Filing
View All SEC Filings ➞
Atossa Therapeutics
Atossa Therapeutics logo
Country United States
IPO Date Nov 8, 2012
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Steven C. Quay

Contact Details

448 NW Market Street Seattle, Washington 98107 United States

Stock Details

Ticker Symbol ATOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001488039
CUSIP Number 04962H704
ISIN Number US04962H7044
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.